Effect of boron neutron capture therapy for melanotic and amelanotic melanoma transplanted into mouse brain.
In order to develop a protocol to treat brain metastatic melanoma using our 10B-p-boronophenylalanine (BPA) boron neutron capture therapy (BNCT), we initiated the following studies (i), Comparative analyses of boron biodistribution between melanoma proliferating in the brain and skin among melanotic and amelanotic types, and (ii) Therapeutic evaluation of BPA-BNCT for brain melanoma models of both types, using survival times. Our present data have revealed that boron concentration in melanoma proliferating in the brain, the major prerequisite for successful BNCT, showed a positive correlation to melanin synthesizing activity in the same way as melanoma proliferating in skin. Further, the boron concentration ratio of melanoma to normal surrounding tissue for brain melanoma models was considerably higher than that for subcutaneous (s.c.) ones because of the existence of the blood-brain barrier (BBB). Additionally, from analyses of median and mean survival times following BNCT using low, middle, and high neutron doses, the therapeutic effect of BNCT for the amelanotic A1059 melanoma appeared at first glance to be higher than that for the highly BPA attracting and highly relative biological effect equivalent dose obtaining B15b melanoma. As the survival time was dependent on both regression and regrowth curves, and because the brain melanoma model in small animals made it difficult to evaluate these curves separately, we further examined the in vivo growth curve of both types of melanomas following implantation in s.c. tissue. The melanotic B15b melanoma was indeed found to possess much higher growth rate as compared with that of the amelanotic A1059 melanoma. The significance of boron biodistribution studies and BNCT survival curve analyses in forming an effective clinical protocol for individual human cases of melanoma brain metastasis is discussed.
Iwakura
Masaki
M
Department of Neurosurgery, Kobe University School of Medicine, Japan.
Kondoh
Hirofumi
H
Hiratsuka
Junichi
J
Ehara
Kazumasa
K
Tamaki
Norihiko
N
Mishima
Yutaka
Y
D000818:Animals; D001895:Boron / Q000378:metabolism; D001896:Boron Compounds / Q000378:metabolism* / Q000627:therapeutic use; D016754:Boron Neutron Capture Therapy / Q000379:methods; D001921:Brain / Q000378:metabolism* / Q000473:pathology; D001932:Brain Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000532:radiotherapy; D007554:Isotopes; D008543:Melanins / Q000096:biosynthesis; D018328:Melanoma, Amelanotic / Q000378:metabolism* / Q000473:pathology / Q000532:radiotherapy; D008546:Melanoma, Experimental / Q000378:metabolism* / Q000473:pathology / Q000532:radiotherapy; D051379:Mice; D008810:Mice, Inbred C57BL; D009368:Neoplasm Transplantation; D010649:Phenylalanine / Q000031:analogs & derivatives / Q000378:metabolism* / Q000627:therapeutic use; D011838:Radiation-Sensitizing Agents / Q000378:metabolism* / Q000627:therapeutic use; D014407:Tumor Cells, Cultured
D001896:Boron Compounds; D007554:Isotopes; D008543:Melanins; D011838:Radiation-Sensitizing Agents; D010649:Phenylalanine; D001895:Boron; C033685:4-boronophenylalanine